Edible and Medicinal Mushrooms in Metabolic Syndrome: From Mechanistic Plausibility to Clinical Evidence—A Narrative Review
- 1Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, 24 Broniewskiego Street, 71-460 Szczecin, Poland
Abstract
Background: Edible and medicinal mushrooms contain bioactive compounds potentially relevant to metabolic syndrome (MetS). Methods: This narrative review was based on searches of PubMed and Embase from database inception to 10 April 2026. In vitro, in silico, animal and human studies, and systematic reviews were considered. Evidence was mapped by species, preparation, evidence level and outcome, distinguishing MetS diagnostic components from related outcomes. Results: The evidence was predominantly preclinical and addressed glucose and lipid metabolism, adiposity, inflammation, oxidative stress and gut microbiota. Human evidence was dominated by Ganoderma lucidum. The only randomized trial in participants with diagnosed MetS that assessed its diagnostic components (n = 84) found no effect of G. lucidum, alone or combined with Cordyceps sinensis, on glycemia, blood pressure, lipids, waist circumference or MetS status. Systematic reviews reported no significant effects on fasting blood glucose, blood pressure or lipid profile and a small reduction in body mass index without a corresponding change in waist circumference, although the certainty of evidence was very low. Individual, unreplicated trials reported improvements in specific components. Conclusions: Mechanistic plausibility has not translated into demonstrated clinical efficacy. Insufficient chemical characterization and standardization of preparations preclude species-specific recommendations. Trials of standardized preparations in participants with diagnosed MetS are needed.
Related
- Natural Products in Diabetes Mellitus: A Narrative Review of Mechanistic Insights into Metabolic Regulation and Therapeutic Potential
- Potential preventive effects of forest bathing/Shinrin-yoku on depressive symptoms: a narrative review of mechanistic evidence
- Obesity and Oral Health: Clinical Associations, Mechanistic Evidence, and Implications for Dental Care—A Narrative Review
- Understanding Venous Remodeling After Minimally Invasive and Noninvasive Treatments for Varicose Veins: A Mechanistic Narrative Review
- Early mobilization in neurocritical care as a threshold-regulated intervention: a narrative review of mechanistic integration and implications for neurological recovery and physiological stability
BibTeX
@article{melkis2026edible,
title = {{Edible and Medicinal Mushrooms in Metabolic Syndrome: From Mechanistic Plausibility to Clinical Evidence—A Narrative Review}},
author = {Klaudia Melkis and Karolina Wrońska and Natalia Antoniewska and Joanna Walczyńska and Amelia Kostrzewa and Kinga Szymczykowska and Karolina Jakubczyk},
journal = {Nutrients},
year = {2026},
month = nov,
doi = {10.3390/nu18213646},
url = {https://www.mdpi.com/2072-6643/18/21/3646},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Edible and Medicinal Mushrooms in Metabolic Syndrome: From Mechanistic Plausibility to Clinical Evidence—A Narrative Review
AU - Klaudia Melkis
AU - Karolina Wrońska
AU - Natalia Antoniewska
AU - Joanna Walczyńska
AU - Amelia Kostrzewa
AU - Kinga Szymczykowska
AU - Karolina Jakubczyk
PY - 2026
DA - 2026/11/02
JO - Nutrients
DO - 10.3390/nu18213646
UR - https://www.mdpi.com/2072-6643/18/21/3646
AB - Background: Edible and medicinal mushrooms contain bioactive compounds potentially relevant to metabolic syndrome (MetS). Methods: This narrative review was based on searches of PubMed and Embase from database inception to 10 April 2026. In vitro, in silico, animal and human studies, and systematic reviews were considered. Evidence was mapped by species, preparation, evidence level and outcome, distinguishing MetS diagnostic components from related outcomes. Results: The evidence was predominantly preclinical and addressed glucose and lipid metabolism, adiposity, inflammation, oxidative stress and gut microbiota. Human evidence was dominated by Ganoderma lucidum. The only randomized trial in participants with diagnosed MetS that assessed its diagnostic components (n = 84) found no effect of G. lucidum, alone or combined with Cordyceps sinensis, on glycemia, blood pressure, lipids, waist circumference or MetS status. Systematic reviews reported no significant effects on fasting blood glucose, blood pressure or lipid profile and a small reduction in body mass index without a corresponding change in waist circumference, although the certainty of evidence was very low. Individual, unreplicated trials reported improvements in specific components. Conclusions: Mechanistic plausibility has not translated into demonstrated clinical efficacy. Insufficient chemical characterization and standardization of preparations preclude species-specific recommendations. Trials of standardized preparations in participants with diagnosed MetS are needed.
SN - 2072-6643
ER -